MedPath

n3 PUFA and Muscle-disuse Atrophy in Young Women

Not Applicable
Completed
Conditions
Muscle Atrophy
Interventions
Dietary Supplement: n3 PUFA-enriched fish oil
Dietary Supplement: Placebo
Registration Number
NCT03059836
Lead Sponsor
McMaster University
Brief Summary

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Detailed Description

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • Female
  • Aged 18-30 years
Read More
Exclusion Criteria
  • Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded
  • A history of neuromuscular problems or muscle and/or bone wasting diseases
  • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
  • Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
  • Fish allergy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
n3 PUFAn3 PUFA-enriched fish oilIntervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
PlaceboPlaceboIntervention: Organic Sunflower Oil 5000mg per day
Primary Outcome Measures
NameTimeMethod
Muscle VolumeBaseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization

Change in Muscle Volume Measured by Magnetic Resonance Imaging

Secondary Outcome Measures
NameTimeMethod
Skeletal Muscle StrengthBefore (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

Change in Skeletal Muscle Strength

Muscle Lipid CompositionBaseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

Change in Muscle Lipid Composition

Integrated Rates of Muscle Protein SynthesisBefore (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization

Change in Muscle Protein Synthesis

Trial Locations

Locations (1)

Exercise Metabolism Research Laboratory, McMaster Univeristy

🇨🇦

Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath